Who are Infliximab-Dyyb's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Certolizumab Pegol (CZP), TDM-based infliximab intravenous therapy, etanercept or adalimumab, Infliximab Adalimumab y Golimumab, infliximab, etanercept, adalimumab, Adalimumab, etanercept, infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/infliximab-dyyb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Infliximab-Dyyb — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infliximab-Dyyb (Infliximab-Dyyb) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor; monoclonal antibody. Area: Immunology.

marketed TNF-alpha inhibitor; monoclonal antibody TNF-alpha (TNFα) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Infliximab-Dyyb (Infliximab-Dyyb) — Asan Medical Center. Infliximab-dyyb is a TNF-alpha inhibitor monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha, blocking its pro-inflammatory signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Infliximab-Dyyb TARGET	Infliximab-Dyyb	Asan Medical Center	marketed	TNF-alpha inhibitor; monoclonal antibody	TNF-alpha (TNFα)
Certolizumab Pegol (CZP)	Certolizumab Pegol (CZP)	UCB Pharma	marketed	TNF-alpha inhibitor	TNF-alpha
TDM-based infliximab intravenous therapy	TDM-based infliximab intravenous therapy	Asan Medical Center	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
etanercept or adalimumab	etanercept or adalimumab	University of Glasgow	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Infliximab Adalimumab y Golimumab	Infliximab Adalimumab y Golimumab	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
infliximab, etanercept, adalimumab	infliximab, etanercept, adalimumab	University Hospital, Strasbourg, France	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Adalimumab, etanercept, infliximab	Adalimumab, etanercept, infliximab	University of Padova	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor; monoclonal antibody class)

Asan Medical Center · 1 drug in this class
Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Infliximab-Dyyb — Competitive Intelligence Brief. https://druglandscape.com/ci/infliximab-dyyb. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab